ABSTRACTS

Abstract Deadline Extended!

Submit your abstract by November 20th.

Submit Your Abstract Here

Key Dates

Please note, dates are subject to change.

NOVEMBER 20, 2026
Abstract Submission Site Closes.

DECEMBER 16, 2026
Oral and Poster Announcement.

FEBRUARY 8, 2027
Late Breaking Abstract Submission Site Closes.

Abstract Categories:

  • Melanocyte Biology

  • Prevention and Early Detection

  • Tumor Plasticity and Resistance

  • Immunology

  • Innovative Technologies and Biomarkers

  • Difficult and Rare Melanomas

  • Clinical Research

  • Epidemiology

  • Other

Abstract Guidelines:

  • Abstracts submitted by e-mail, post, or fax will not be considered.

  • Incomplete applications will not be considered.

  • Abstracts must be written in English, the official language of the congress.

  • Tables and charts are not permitted in the abstract submission.

  • List affiliations of author(s) as briefly as possible with city, state (if applicable), and country.

  • Use standard and well-accepted abbreviations only.

  • The person who is submitting the abstract is the “submitting author" and will be the main point of contact for that abstract. All correspondence will be directed to the submitting author only. They will be responsible for communication with all authors associated with the abstract(s). Third parties or other authors are not authorized to discuss the submitted abstract and will not be provided with any information.

  • You will need to indicate the name of the presenting author at the congress. This is the person who will present the oral and poster presentation during scheduled times if accepted.

  • If you would like to submit additional abstracts, please complete the Abstract Submission form and begin the submission process again from the beginning.

  • Upon acceptance, your abstract will be published in the PCMR journal exactly as it was entered into your submission. Please be sure all information is entered correctly (i.e. capitalization, spelling, grammar, etc.)

  • Abstract content should be single-spaced and typed in lowercase. You have up to 2,500 characters (counting spaces) that includes the abstract body (does not include authors and affiliations). Please do NOT separate this section with sub headers (i.e. methods, results, conclusions).

  • Previously published/presented abstracts will be reviewed. However, the scientific committee is looking for unpublished work to be presented at the congress.

Poster Guidelines:

  • Posters will be displayed in-person and through the conference app.

  • Posters must be no larger than 48 inches wide x 48 inches high. Posters that exceed this size will not be displayed.

  • Warrant that he/she is an investigator with substantial involvement in the study presented in the abstract.

  • Posters can be displayed starting 12:00pm on Sunday, March 7.

  • Posters must be removed no later than 7:00pm on Tuesday, March 9. Any remaining posters will be disposed of.

  • High traffic times for poster viewing will be during lunch breaks and poster receptions.

  • SMR is committed to minimizing commercial bias in poster presentations and handouts. Poster presentations should not contain any of the following: commercial logos, company names, brand or proprietary drug names.

  • Suggestions for formatting posters:

    • Place the heading in large-sized font at the top of the poster.

    • List the title and all authors.

    • All content should be readable from a distance of three feet or more.

    • Make all print dark on a light background.

    • Use letters, arrows, numbers, or other devices to show those who will be viewing your poster the preferred sequence in which your poster should be reviewed.

    • Charts, drawings, and illustrations should be similar to those you would use in making PowerPoint slides

    • If photographs are used, have them processed with a matte or dull finish

    • The poster can either be made on one sheet (rollup) or in several small sections. Do NOT mount illustrations on heavy cardboard because they may be difficult to keep in position on the poster board.

    • Write your presentation concisely and keep captions brief.

    • The poster should be self-explanatory so that you are free to supplement the information and discuss particular points raised by questions during the poster session.

  • The first/submitting author must agree to the following:

    • Release full copyright to SMR and give full permission for the abstract, if accepted, to be published in the 2027 SMR Abstract book in electronic format, as well as published through PCMR.

    • Warrant that they are an investigator with substantial involvement in the study presented in the abstract.

    • Confirm that all authors are aware of, and agree to, the content of the abstract and support the data therein; furthermore, the submitting author will be responsible for obtaining, and, upon request, showing proof that all authors have given their permission for the submission of the abstract and content therein as well as for the potential inclusion of the abstract in the official 2027 SMR Congress Program.

    • Upon acceptance, your abstract will be published in the PCMR journal the exact way it is entered into your submission. Please be sure all information is entered correctly (i.e. capitalization, spelling, grammar, etc.)

    • Accept responsibility for the accuracy and confidentiality of the submitted abstract.

    • Acknowledge any editorial assistance on the printed poster or oral presentation (not in the abstract body) in the writing of the abstract that was provided by a third party, providing the name of the writer and the company who provided this service.

    • Fully declare all financial support of the work presented.

    • Ensure that all authors identify any financial interest in products or processes involved in their work. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships.

    • Ensure that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and that properly informed consent, where appropriate, has been given.

    • The purpose of late breaking abstracts is to allow for presentation of the most up-to-date clinical research.

    • Due to space constraints, submissions that are not considered to be late-breaking, will not be considered for posters.

  • If the submitting author wishes to withdraw their abstract from the 2027 SMR Congress after outcome notifications have been made available, they must submit a written request within 48 hours to SMR@sswmeetings.com. Any abstract withdrawal requests made after 48 hours from notification cannot be assured of removal from the 2027 SMR Congress Abstract Book.

    • Abstracts accepted for presentation (either Proffered Paper/Oral presentation or Poster Presentation) will be published in the Congress Abstract Book.

    • Your abstract will be published exactly as it is submitted.

    • Please ensure accuracy of your submitted abstract on or before the deadline of November 9, 2027, at 11:59 p.m. EST.

    • Please do not create a new submission for abstracts requiring edits or completion.

    • Accepted Abstracts should not be published online or in print prior to the beginning of the official Congress session during in which they are presented.

    • Authors may disclose or announce that their abstract has been accepted for presentation at the congress, including announcements via press release.

    • Abstracts will be available online. As soon as they are available, disclosure or announcement of the data published in the abstract is fully permissible.

    • A press release describing the full details of the presentation can be timed for release on the day of presentation at the congress, not prior.

Questions? Contact us at SMR@sswmeetings.com or (518)-399-7181.